Form 4: Arcellx Merger Completion & Executive Stock Transactions

Arcellx, Inc. reports completion of its merger with Gilead Sciences, Inc., detailing executive stock option conversions and beneficial ownership changes.

Summary

• Arcellx, Inc. has completed its merger with Gilead Sciences, Inc. as of April 28, 2026.
• Ali Behbahani, a Director, reported transactions related to the merger.
• Common stock tendered in the offer was exchanged for $115.00 per share in cash, plus one contingent value right (CVR) per share, representing a potential additional $5.00 payment.
• Outstanding stock options with an exercise price below the $115.00 closing amount were canceled and converted into a right to receive a cash payment equal to the difference between the closing amount and the exercise price, plus one CVR per optioned share.
• Ali Behbahani's beneficial ownership is held through the Ali Behbahani Revocable Trust dated June 26, 2015.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, as it confirms the successful completion of a significant acquisition at a premium valuation for shareholders and provides clarity on the conversion of executive stock options.

Positives

• The merger with Gilead Sciences, Inc. has been successfully completed, providing a cash payout of $115.00 per share plus a CVR for Arcellx shareholders.
• Executive stock options with exercise prices below $115.00 were converted into cash payments and CVRs, potentially benefiting option holders.
• The transaction provides a clear exit for shareholders and option holders.

Negatives

• Stock options with exercise prices above the $115.00 closing amount would not result in a cash payment beyond the CVR, as the excess would be zero or negative.

Risks

• The value of the Contingent Value Right (CVR) is contingent and not guaranteed, with a potential payment of $5.00 per CVR.
• Withholding taxes will apply to cash payments received from the merger and option conversions.

Future Outlook

The future outlook for Arcellx shareholders and option holders is tied to the successful realization of the contingent value rights, which are subject to specific terms and conditions outlined in the contingent value rights agreement.

Management Comments

• The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the 1934 Act, as amended, or otherwise of such portion of the securities held by the Behbahani Trust in which the Reporting Person has no pecuniary interest.

Industry Context

StockSavvy.ai notes that this Form 4 filing details the completion of a significant M&A event in the biotechnology sector, where larger pharmaceutical companies like Gilead Sciences frequently acquire innovative smaller firms to bolster their pipelines. The structure of the deal, including cash and contingent value rights, is a common mechanism to bridge valuation gaps and incentivize continued performance post-acquisition.

Stakeholder Impact

• Shareholders: Receive $115.00 cash per share plus a CVR, representing a significant return on investment.
• Option Holders: Receive cash payments for options with exercise prices below $115.00, plus CVRs, providing value realization for their equity awards.
• Employees: May be impacted by changes in employment terms and conditions following the acquisition by Gilead Sciences.
• Creditors: The transaction is structured as an acquisition, and the impact on existing creditors will depend on the terms of the merger and any subsequent integration plans by Gilead Sciences.

Next Steps

• Shareholders and option holders will receive the specified cash payments and CVRs.
• The contingent value of the CVRs will be realized based on the achievement of certain milestones as defined in the contingent value rights agreement.

Key Dates

Recommendation

The filing confirms the completion of the acquisition at the announced terms, which is a significant event. However, as the company is now acquired, the focus shifts to the performance of the CVRs. For existing shareholders, holding until the CVR milestones are resolved or the value is realized is a reasonable approach, while new investment decisions would depend on Gilead Sciences' strategic plans for the acquired assets.

Keywords

Arcellx, ACLX, Gilead Sciences, Merger, Acquisition, Form 4, SEC Filing, Stock Options, Contingent Value Right, Beneficial Ownership, Ali Behbahani, Director